What's new in pharmaAugust 1, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Justin Sullivan/Getty Images STAT+ | AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills Advocacy groups argued Gilead exploited the federal government by using the benefits of intellectual property to charge ever-higher prices By Ed Silverman Opinion: The U.S. needs a revolution to harness the potential of GLP-1s for weight loss Where is the national plan to facilitate the widespread, safe delivery to eligible Americans of GLP-1s like Novo Nordisk's Wegovy and Eli Lilly's Zepbound? By Gavin Hart FDA to stress opioids' risk of overdose, death in new medication safety labels The decision comes nearly 30 years after initial approval of OxyContin, the now-infamous painkiller sold by Purdue Pharma. By Lev Facher Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman What Vinay Prasad's ouster means for biotech and the FDA STAT reporters discuss how the removal of Vinay Prasad from the FDA will affect the biopharma industry and the agency. By Elaine Chen, Adam Feuerstein, and Matthew Herper STAT+ | MAGA influencers take a sudden interest in Medicare Advantage reforms, echoing a dark money group Pro-Trump influencers trained their fire on Sen. Bill Cassidy after he proposed reforms to Medicare Advantage By Casey Ross and John Wilkerson More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments